Replies to post #10 on $Amazing $Biotech & $olid $Microcap $tocks

[ash111]

ADHD looking interesting kei. I will do DD later including Numbers and post here. their balance sheet is Solid and no need to raise money till the least 2017 Year-End from a quick look.

[kei]

ADHD - $2.52 mentioned here at $2.12 a week ago..(holding all)

ADHD $2.12..just bought some shares here..it is very interesting since if the FDA lifts halt of the clinical trial, the pps will jump…according to the company pr, we will hear the news probably on or around next Friday? ..here is the company pr on 12/14/2016

www.alcobra-pharma.com/releasedetail.cfm?ReleaseID=1004138

also here is ash's dd:
ADHD 2.16 +2.9%, Full DD: Cash, marketable securities, and deposits totaled $54.3 million at
September 30, 2016 compared with $61.1 million at June 30, 2016 and $69.7 million at the end of 2015.

Recent Presentation highlights:

1. Cash Position support activity thru mid-2018.
2. IP Portfolio- 50 Registered Patents, Protection extents to 2028.
3. 2015 total ADHD sales in US: $9.6B

http://seekingalpha.com/article/4024599-alcobra-adhd-investor-presentation-slideshow

27,562,795 o/s. a/o September 30,2016.

Solid Balance sheet: Total current assets $52m Total current liabilities $3.3m

Ratio of 15.7 (Very Solid).

A strong Ownership -Institutional Holdings
63.15%, including Baker Bros : http://www.nasdaq.com/symbol/adhd/ownership-summary

Teva ($50B co.) invested $2.2 million in Alcobra (ADHD) in 2011."Teva received options to purchase full ownership of Alcobra, but in January 2012, following then Teva CEO Shlomo Yanai's resignation, it did not exercise the options and the acquisition deal was cancelled".
read more: http://www.haaretz.com/israel-news/business/alcobra-to-be-first-israeli-nasdaq-ipo-of-2013-1.494310

Worst Scenario already priced in, Share price near 52 wk. low. 01/13/2017 Phase 3:
Clinical hold placed September 29, 2016. Noted December 14, 2016 that it intends to given an update from its meeting with the FDA in “the coming weeks” - Latest estimated date - January 13, 2017 assuming that “coming weeks” is defined as less than four weeks.

03/31/2017 Phase 2/3:
Phase 2/3 initiated June 2016. Initial top-line data are due 1Q 2017 as per latest company presentation.
http://biopharmcatalyst.com/calendars/fda-calendar

Risk vs Reward + solid Cash Position, could be interesting.